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Mohammad G. Saklayen1* and Neeraj V. Deshpande2
1V.A. Medical Center, Wright State University Boonshoft School of Medicine, Dayton, OH, USA, 2Ohio State University, 
Columbus, OH, USA
It is surprising that only about 50 years ago hypertension was considered an essential 
malady and not a treatable condition. Introduction of thiazide diuretics in late 50s made 
some headway in successful treatment of hypertension and ambitious multicenter VA 
co-operative study (phase 1 and 2) started in 1964 for diastolic hypertension ranging 
between 90 and 129 mmHg and completed by 1971 established for the first time that 
treating diastolic hypertension reduced CV events such as stroke and heart failure 
and improved mortality. In the following decade, these results were confirmed for the 
wider US and non-US population, including women and goal-oriented BP treatment 
to diastolic 90 became the standard therapy recommendation. But isolated systolic 
hypertension (accounting for two-thirds of the 70 million hypertensive population in USA 
alone) was not considered treatable until 1991 when SHEP study (systolic hypertension 
in elderly program) was completed and showed tremendous benefits of treating systolic 
BP over 160 mmHg using only a simple regimen using small dose chlorthalidone with 
addition of atenolol if needed. In the next two decades, ALLHAT and other studies 
examined the comparability of outcomes with use of different classes and combinations 
of antihypertensive drugs. Although diastolic BP goal was established as 90 in the late 
70s and later confirmed by HOT study, the goal BP for systolic hypertension was not 
settled until very recently with completion of SPRINT study. ACCORD study showed no 
significant difference in outcome with sys 140 vs. 120 in diabetics. But recently com-
pleted SPRINT study with somewhat similar protocol as in ACCORD but in non-diabetic 
showed almost one-quarter reduction in all-cause mortality and one-third reduction of 
CV events with systolic BP goal 120.
Keywords: hypertension, randomized controlled trials, history, treatment outcome, multicenter trial
Abbreviations: BP, blood pressure; HTN, hypertension; Dias, Diastolic; Sys, systolic; CV, cardiovascular; CVD, cardiovascular 
death; MI, myocardial infarction; CKD, chronic kidney disease; ARR, absolute risk reduction; RR, relative risk reduction. 
Drugs: CCB, calcium channel blocker; BB, beta blocker; ACEI, angiotensin converting enzyme inhibitor; HCTZ, hydrochlo-
rothiazide; CTDN, chlorthalidone; AB, alpha blocker; ARB, angiotensin receptor blocker. Trials: VACoop, Veterans Affairs 
Co-operative studies; HDFP, hypertension detection and follow-up trial; MRFIT, multiple risk factor intervention trial; 
MRC, Medical Research Council (UK); EWHPE, European Working Party High Blood pressure in the Elderly; SHEP, systolic 
hypertension in the elderly program; TOMHS, treatment of mild hypertension study; DASH, dietary approaches to stop 
hypertension; HOT, hypertension optimal treatment; UKPDS, United Kingdom Prospective Diabetes Study; AASK, African-
American Study of Kidney Disease; ALLHAT, antihypertensive and lipid lowering treatment to prevent heart attack trial; 
ANBP, Australian National Blood Pressure Study; ASCOT-BPLA, Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure 
Lowering Arm; CAFÉ, Conduit Artery Function Evaluation; HYVET, hypertension in the very elderly trial; ACCOMPLISH, 
avoiding cardiovascular events through combination therapy in patients living with systolic hypertension; ACCORD, Action 
to Control Cardiovascular Risk in Diabetes; SPRINT, systolic blood pressure intervention trial.
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Over the last several decades, the term “essential hypertension” 
has become entrenched in our medical vocabulary. We not only 
use it in our usual medical lingo but the term was actually codi-
fied in ICD-9. As a medical community, we do not categorize any 
other common pathological conditions, such as obesity, NIDDM, 
or CAD as “essential.”
Moreover, in order to distinguish the common variety of 
hypertension from a specific etiology-related hypertension – so-
called secondary hypertension – the most logical alternate term 
would have been “primary” hypertension. But why and how did 
the term “essential hypertension” come about? To find the answer, 
one needs to delve into the history of the pharmacological treat-
ment of hypertension.
The history of hypertension goes back a long way (1). In 
ancient Chinese and Indian Ayurvedic medicine, the quality of 
an individual’s pulse, as felt by gentle palpation by the trained 
physician, was a window into the condition of the cardiovascular 
system. What was called “hard pulse” possibly would qualify for 
the modern term of hypertension. Any article on the history of 
hypertension, however, is incomplete without a mention of Akbar 
Mahomed’s contribution in developing the modern concept of 
hypertension. In the late nineteenth century, Frederick Akbar 
Mahomed (1849–1884), an Irish-Indian physician working at 
Guy’s hospital in London, first described conditions that later 
came to be known as “essential hypertension,” separating it from 
the similar vascular changes seen in chronic glomerulonephritis 
such as Bright’s disease. Some of the noteworthy contributions 
of Akbar Mahomed were the demonstration that high BP could 
exist in apparently healthy individuals, that high BP was more 
likely in older populations, and that the heart, kidneys, and brain 
could be affected by high arterial tension (Interested readers may 
read about Akbar’s life in a detailed account written by Cameron 
in Kidney international) (2, 3). However, only with the advent of 
the mercury sphygmomanometer in the early twentieth century 
and defining of the systolic and diastolic BP by appearance/
disappearance of Korotkoff sounds as heard via the stethoscope, 
the modern quantitative concept of hypertension – broken into 
systolic and diastolic categories – came into existence. By the mid-
dle of the twentieth century, checking BP by sphygmomanometer 
became part of the routine physical examination in hospitals and 
clinics (4).
Hypertension, however, was not always considered a disease 
as we know it now. President Franklin D. Roosevelt was given 
a clean bill of health by his physician even when his BP was 
recorded as ~220/120. A few years later while at Yalta, Winston 
Churchill’s personal physician noted in his diary that President 
Roosevelt “appeared to be have had signs of ‘hardening of the 
arteries disease’ and had a few months to live.” Subsequent events 
demonstrated the truth of his diagnosis. President Roosevelt 
ultimately had a fatal hemorrhagic stroke 2  months later, and 
his death brought hypertension’s potential as a deadly malady to 
the lime light (5).
Three years after Roosevelt’s death, the pivotal National 
Heart Act was signed into law by President Truman. The Act 
created the path for the study of heart diseases and resulted 
in several studies including the Framingham Heart Study. The 
Framingham studies consistently showed that hypertension, 
such as hyperlipidemia, was associated with many cardiovascu-
lar morbidities such as stroke, heart failure, and heart attacks 
leading to premature deaths and the risk was clearly higher with 
higher blood pressure (systolic and diastolic). Even before the 
Framingham studies, many insurance companies had already 
begun measuring BP for policyholders’ physical examinations. 
Furthermore, several studies done by the Actuarial Society of 
America pointed toward the higher morbidity and mortality 
associated with higher BP (6, 7).
Yet, throughout the 1960s, the debate continued in the medi-
cal community regarding whether a need existed for treating the 
common variety of hypertension, by then aptly named “essential 
hypertension” because it was deemed an unavoidable, hence 
essential, component of the aging process. Attempts to treat 
hypertension, with the few drugs that were available at the time, 
often caused more misery and earlier demise for the patients than 
leaving them untreated. The prevailing attitude in the academic 
community was expressed in an editorial in the Archive of Internal 
medicine in 1965 by two professors of medicine from New York.
To quote
It is common experience that many patients live medi-
cally uneventful lives in spite of prolonged and consid-
erable blood pressure elevation. In our study group’s 
experience with 241 living and continuously employed 
hypertensive patients, followed from 10–25 years, a so 
called benign course was the rule, not the exception … A 
drug that will maintain BP in the normal range in the 
supine as well as upright position without adverse physi-
ological effects for all 24 hours over a period of years, 
when and if available, may well make medical history …
One needs only to look back at the past 50  years 
to be amazed and deeply concerned at the worldwide 
enthusiasm generated by many proposed therapies 
for hypertension which eventually met their deserved 
doom – oblivion…
Acceptable techniques for obtaining the necessary 
proof are presently not available. We believe that critical 
techniques designed for a more precise and scientific 
answer to the problem under discussion will appear 
much sooner in an atmosphere of less enthusiasm and 
more caution in interpreting the results and implication 
of this form of therapy (8).
For more details on this controversy, interested readers are 
referred to Dr. Moser’s review on the early years of hypertension 
treatment (9).
Some reconciliation was therefore necessary between the 
two opposing views: is the common variety of hypertension, or 
essential hypertension, a benign condition or is it a killer dis-
ease? Serendipitously, as it happened for many other important 
breakthroughs in science, a few lucky developments occurred 
around the same time and helped in resolving the ongoing 
controversy.
 1. The first Randomized placebo-Controlled clinical Trial 
(RCT) in the history of medicine was conducted by Medical 
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FiGURe 1 | vA-co-op study phase 1 followed by 2 established for the first time that diastolic HTN > 90 to 129 was treatable with available drugs and 
reduced stroke, CHF, and mortality. HDFP study affirmed that BP treatment target to diastolic goal of 90 gave much better CV outcome results than usual BP 
treatment. MRC and EWHPE confirmed this for younger and older patients, respectively, in non-US population. MRFIT study showed that of three risk factors for 
CHD (hyperlipidemia, smoking, and hypertension) only hypertension was effectively treatable by drugs available that time. SHEP study broadened the definition of 
treatable hypertension to include isolated systolic hypertension, treatment of which in elderly gave profound CV and mortality benefits. DASH study convincingly 
showed the benefits of Mediterranean type diet in lowering BP and that salt restriction adds to that benefit. HOT study established that lowering diastolic BP goal 
<90 (85 or 80) does not add any further benefits. TOMHS and MRC 2 were relatively minor studies. UKPDS Hypertension studies showed that moderately tight BP 
control <150/85 goal-reduced diabetic mortality by 32% – much higher level of benefits than in non-diabetics. AASK study was done in African-Americans with 
CKD and showed that tight BP control over usual BP control did not affect CKD progression but use of ACEI caused superior reno-protection over CCB. ALLHAT 
study showed that use of thiazide drugs (Chlorthalidone) did not increase incidence of MI or mortality over other classes of drugs (CCB, ACEI, or AB). It also showed 
incidence of CHF was more with use of AB, CCB, and ACEI than CTDN. ASCOT study showed superiority of combination of ACEI and CCB over BB and thiazide 
(HCTZ) in preventing CV outcomes. CAFE, a sub study of ASCOT showed that BB failed to lower central aortic BP as opposed to peripheral BP. HYVET showed 
that treatment of hypertension in very elderly (>80) is even more beneficial than in any other age group. ACCOMPLISH study showed superiority of combination of 
ACEI and CCB over ACE and thiazide (HCTZ and not CTDN) for CV outcomes. ACCORD study showed that in diabetics, lowering BP target to 120 sys over 
conventional 140 added no further reduction in CV or renal outcomes. SPRINT study showed significant mortality and cardiovascular benefits in group with Systolic 
BP treatment goal of 120 compared to goal of 140 in non-diabetic patients.
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Research Council (MRC of UK) in 1948 (studying the effec-
tiveness of streptomycin for the treatment of tuberculosis). 
This provided the tool for scientific proof of efficacy of any 
treatment (10).
 2. Thiazides and thiazide-like compounds were developed from 
the sulpha molecule and they were found to have natriuretic 
properties. First to come was chlorothiazide, followed by 
hydrochlorothiazide, and then chlorthalidone a few years 
later. These drugs showed potent hypotensive effects. Small 
studies demonstrated thiazides’ tolerability and effectiveness 
of this new group of drugs in lowering BP (11).
 3. Arthur Guyton, the famous renal physiologist, developed 
his theory of pressure natriuresis and hypothesized that 
abnormal pressure natriuresis curves can explain all types of 
hypertension (12).
 4. The Veterans Administration Medical Centers  –  a chain 
of federal hospitals dedicated to the care of war veter-
ans  –  added to their missions of clinical care and medical 
education the lofty goals of pursuing medical research. Thus, 
the VA Co-operative research program was started. Having 
the VA hospital system with many hospitals, scattered across 
USA, under one authority, made it possible for large multi-
center clinical studies to be carried out quickly and with 
relative ease (13).
All of these lucky developments eventually produced the first 
multi-center hypertension treatment trial (the first VA Co-operative 
research study on hypertension), which was published in JAMA 
in 1967. The major findings of these and other landmark studies 
that followed in the subsequent 50 years are highlighted in this 
timeline. Considering the importance of the topic, there had been 
very few attempts to detail the history of hypertension treatment. 
Noteworthy are Dr. Moser’s personal account and a more detailed 
timeline created by Theodore Kotchen (14).
In creating this timeline, I opted to choose studies that were 
landmark in nature and answered a hitherto unresolved question 
regarding management of “essential hypertension.” Subsequent 
studies that reaffirmed these answers or only elaborated on the 
main theme were mostly omitted to keep the timeline short and 
readable. For each selected study, we gave the main hypothesis 
of the study, brief outline of the study methodology and the 
main result(s) along with a brief commentary as to the historical 
importance of the study. I have avoided meta-analyses, however, 
important they may be. We also avoided basic science studies and 
I have purposefully left out newer experimental therapies like 
renal sympathetic ablation therapy for resistant hypertension, 
since it is still evolving.
Following are the brief descriptions of the studies that make up 
the timeline of this review (Figure 1; Table 1).
TABLe 1 | Time line of hypertension.
Study Year Primary question/issues Conclusion of the study/impact
VA-1st 1967 Is severe hypertension (dias) 115–129 treatable Yes, less stroke/CHF
VA-2nd 1970 Same question for moderate BP (90–115) Treated group less stroke/CHF
HDFP 1979 Goal-oriented BP therapy better than usual therapy? Yes. Targeting BP goal of dias 90 reduced CVA by 36% more
MRFIT 1982 Lowering BP and lipid and stopping smoking may  
reduce CHD mortality
No difference in CHD mortality 17.9 vs. 19.3% (per 1000)
MRC 1985 Hypertension treatment in younger patients (35–64) is  
beneficial also?
Yes. Total CV events 286 in treated group vs. 352 in control (p < 0.05)
EWHPE 1986 Hypertension treatment in exclusively older people (60) beneficial? Yes. Mortality reduction 26% decrease in CV mortality 43%
SHEP 1991 Is treatment of systolic hypertension beneficial Treating isolated systolic hypertension over 160 prevented stroke (ARR 3%), 
MI, and all CVD
TOMHS 1993 Outcome of 5 different classes BP meds vs. placebo BP lowering similar among all classes CV events and death reduced  
(ARR 2.2%)
DASH 1997 Does Mediterranean diet with or without salt restriction lowers BP? Compared to western diet it lowers bp and salt restriction adds to the effect
MRC 1997 Salt reduction in older people Lowers BP? Reducing salt intake to 2 g Na lowered BP 7.2/3.2 mmHg
HOT 1998 Lowering Dias BP to 85 or 80 beneficial compared to  
standard 90 goal
No significant benefit in whole study but small benefit in diabetic
UKPDS 1998 Multiple studies 2 involved BP Tight BP control and agents 
(captopril vs. atenolol)
Group target <150/85 had 32, 44, and 34% less death, stroke, and 
retinopathy, respectively. No difference in ACEI group vs. BB
AASK 2002 To reduce progression of CKD BP goal mean 92 better than 105 
ACEI, BB, or CCB better as drug?
No difference in mean BP goal of 92 vs. 105. ACEI use protected 
progression of CKD better than CCB
ALLHAT 2002 Compared to old thiazide (CTDN) new class of BP drugs CCB, 
ACEI, or AB has better outcome? AB gr closed for  
high incidence of CHF
No difference in MI, mortality, or CKD progression among 3 classes. CTDN 
vs. CCB for CHF RR 1.38. CTDN vs. ACEI for stroke and CHF RR  
1.15 and 1.19
ANBP2 2003 ACEI vs. thiazide (HCTZ) for CV outcomes in Australian In this study unlike ALLHAT, ACE was better all CV events RR was 0.88
ASCOT 2005 CCB and ACE inhibitor compared to BB and thiazide  
for BP control
CCB and ace inhibitor combination group showed better CV outcomes
CAFÉ 2006 Why Betablocker for BP does not prevent stroke Betablocker lowers peripheral BP but not central (aortic) BP
HYVET 2008 Should we treat elderly (>80) hypertensive (sys > 160) Yes. Treated group had 30% less stroke and 64% less CHF, 21% less death
AC-SH 2008 Combination of ACEI + CCB better than ACEI + thiazide (HCTZ) ACEI + CCB group had 2.2% ARR of composite CV events and death
ACCRD 2010 In diabetics Goal BP sys < 120 better than 140? No significant difference in mortality, total CV events, or renal protection
SPRINT 2015 Same as ACCORD but in non-diabetic 27% improved all-cause mortality and 25% improvement in primary CV 
outcomes
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TiMeLiNe OF KeY HYPeRTeNSiON 
STUDieS
VA cooperative study phase 1 – 1967
VA co-operative study on HTN. First Randomized controlled 
trial of hypertension treatment anywhere in the world. Truly 
ground breaking study.
The Veterans Administration (VA) cooperative study on 
antihypertensive agents was a major milestone achieved in 
medicine. This was the first adequately powered placebo-
controlled, RCT of antihypertensive therapy (15). The phase 1 
of the study examined active treatment (hydrochlorothiazide, 
reserpine, and hydralazine) vs. placebo in 143 veterans with 
severe hypertension (diastolic blood pressure 115–129 mmHg) 
and achieved an average fall of blood pressure by 43/30 mmHg 
in the treated group. The recruitment started in 1964 and 
average follow-up was about 1.5 years. The results of the study 
showed clear morbidity and mortality benefit, most remarkably 
in reduction in progression to accelerated/malignant hyperten-
sion in the treatment group.
Study summary:
• Total patients – 70 in each group
• BP achieved – 91.6 vs. 119.7
• Events-
 – Death: 4 in control, 0 in treatment group
 – Morbid Events: 27 in control, 2 in Rx group
Morbid events included progression to malignant hyperten-
sion as evidenced by fundal hemorrhage, CVA, MI, heart failure, 
and dissecting aneurysm.
VA cooperative study phase 2 – 1970
This phase of the study examined the benefit of active treat-
ment vs. placebo in moderately severe hypertension (diastolic 
90–115).
Recruitment for this phase started same time in 1964 as 
with the first phase group but being less severe disease, and 
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this study needed larger sample size and longer follow-up. They 
were followed for a longer duration (mean 3.8 years). Using the 
same active treatment as in the first study, this study achieved 
an average fall in diastolic BP by 19  mmHg in the treatment 
group. The results showed significant mortality and morbidity 
benefits (16).
Study summary:
• Inclusion – diastolic BP > 90 < 115
• Total number – 380 all males (186 vs. 194)
• Follow-up – average 3.9 years
• Mean age – 52.0
• Rx – HCTZ, reserpine, hydralazine
• Initial BP – 165/105 vs. 162/104
• Drop out – 15% equally divided
• BP achieved: 138/91 vs. 166/105
• BP dropped average (treatment vs. control)
• 27.2 vs. 4.2 (+) systolic
• −17.4 vs. 1.2 (+) diastolic
• Deaths: 19 vs. 8
• Total morbid events: 56 vs. 22 (29 vs. 12%)
• CVA: 20 vs. 8
• CHF: 11 vs. 0
• Malignant HTN: 4 vs. 0
• CAD: 13 vs. 11
Hypertension Detection and Follow-Up (HDFP) 1979
First study to demonstrate benefit in mortality and morbidity 
by aggressive, goal directed blood pressure treatment with 
stepwise incremental therapy as opposed to more casual BP 
management without trying to reach a target BP. This study 
set the ground rules for future management of BP using incre-
mental therapy – a new concept in managing chronic diseases.
Published in 1979, the Hypertension Detection and Follow-Up 
(HDFP) trial was another land mark trial of antihypertensive 
therapy and was the first study to demonstrate a mortality 
benefit of goal-directed, stepped care blood pressure treatment 
compared to usual care (17). The study established the practice of 
stepped care approach to achieve BP goal which became the norm 
of hypertension treatment strategy ever since. Of note, this study 
exclusively used chlorthalidone (CTDN) as opposed to HCTZ 
and all subsequent NIH sponsored studies did the same.
Study summary:
• Total number: 5485 (Stepped care) vs. 5455 (Usual Care)
• Inclusion: diastolic BP > 90 mm
• Male:Female – 50:40
• Intervention: stepped care vs. usual care
• Drugs: chlorthalidone, reserpine, K-sparing diuretics, meth-
yldopa, hydralazine, guanethidine
• Entry BP: 159/101 vs. 158/101
• BP at goal first year: 51.8 vs. 29.4%
• BP at goal fifth year: 64.9 vs. 43.6%
• Mortality: (6.4 vs. 7.7%) RRR-17%
• CVA: 102 (1.8%) vs. 158 (2.8%) RRR 36%
• CHD: 171 (3.1%) vs. 189 (3.5%)
• Total CV events: 273 (4.9%) vs. 347 (6.4%)
Multiple Risk factor Intervention (MRFIT) 1982
Not a true antihypertension study per se but BP reduction was 
one of the 3 risk factors treated.
The Multiple Risk Factor Intervention Trial (18) was an ambi-
tious randomized primary prevention trial to test the efficacy of 
a multifactor intervention program on mortality from coronary 
heart disease (CHD) in 12,666 high-risk men aged 35–57 years. 
Men were randomly assigned either to a special intervention (SI) 
program consisting of stepped-care treatment for hypertension, 
counseling for cigarette smoking, and dietary advice for lowering 
blood cholesterol levels, or to their usual sources of health care 
in the community.
• Age: 35–37 years
• Study randomization: 12,666
6428 – Intervention (SI)
6438 – Control (UC)
Intervention:
–Dietary counseling
–Smoking counseling
–Treatment of HTN
–Lower cholesterol
• Duration: average 7 years
• Mortality from CHD: 17.9 vs. 19.3 (per 1000)
• Total mortality: 41.2 vs. 40.4 (per 1000)
None of the difference is significant p > 0.5.
The study results played an important role in the direction of 
hypertension treatment in the ensuing decade. The failure of the 
study to achieve reduction in mortality in the intervention group 
was blamed on hypokalemia in some of the thiazide-treated 
patients and newer antihypertensive drugs were promoted by 
pharmaceutical industry over thiazide and thiazide such as 
diuretics like Chlorthalidone. On retrospect, the real cause for 
failure was that the study was planned prematurely. There was no 
Statin yet and arrival of Statin in the 90s made all the difference 
in CAD mortality.
MRC trial of treatment of mild hypertension:  principal 
results 1985
First definitive study to provide evidence of benefits in treat-
ing mild hypertension in younger cohort – men and women 
aged 35–64 years.
The primary objective of the trial (19) was to study the effect 
of the drug treatment of mild hypertension on the rates of stroke, 
of death due to hypertension, and of coronary events in men 
and women aged 35–64 years. The secondary objectives of the 
trial were to compare the effectiveness and adverse effects of two 
antihypertensive drugs bendrofluzide and propranolol.
Study Summary:
  Design: single blind RCT based almost entirely in general 
practices
  No of participants: 17,354
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  Active treatment (bendrofluzide or propranolol): 8700
  Placebo: 8654
  Duration: 5 years
  Stroke: active treatment (60) vs. placebo (109), p < 0.01
  Coronary events: active treatment (222) vs. placebo (234)
  All cardiovascular events: active treatment (286) vs. placebo 
(352), p < 0.05
  Mortality from all causes: active treatment (248) vs. placebo (253)
The authors concluded that to prevent one stroke 850 indi-
viduals would have to receive treatment for a year.
European Working Party High Blood pressure in the 
Elderly (EWHPE) 1986
First major study of hypertension in exclusively elderly 
population
For the EWHPE trial (20, 21), 840 men and women over 60 years 
old, with a systolic blood pressure in the range 160–239 mmHg 
and a diastolic pressure in the range 90–119 mmHg, were ran-
domized to receive active treatment (hydrochlorothiazide with 
triamterene) or matching placebo.
Study Summary: overall
• A non-significant change in total mortality rate (−9%).
• Reduction in cardiovascular mortality (−27%, p = 0.037)
• Decrease in cardiac mortality (−38%, p  =  0.036) and an 
insignificant
• Decrease in cerebrovascular mortality (−32%, p = 0.16).
Study results double-blind part of the trial:
• Decrease in total mortality rate (−26%, p = 0.077).
• Decrease in cerebrovascular mortality on treatment 
(−43%, p = 0.15).
• Decrease in cardiac deaths (−47%, p = 0.048).
• Decrease in deaths from myocardial infarction 
(−60%, p = 0.043).
Systolic Hypertension in the Elderly Program (SHEP) 1991
First randomized controlled trial to show benefits of  treating 
isolated systolic hypertension which prior to this most 
 remarkable study was considered benign or not amenable 
to treatment, though isolated systolic hypertension showed 
more associations with CV morbidities and  mortalities per 
Framingham and other studies. The success of this study opened 
up the  treatment option to 50 million people in US alone.
Up until the 1990s, the benefit of treating isolated systolic 
hypertension (ISH) was an area of uncertainty. The trial was 
designed to examine if the treatment of systolic hypertension 
alone when diastolic BP is normal can be beneficial.
SHEP Study (22) Summary:
Design: double-blind Placebo controlled RCT
Inclusion: systolic BP > 160 mmHg, diastolic BP < 90 mmHg 
with age >60 years.
Total participants 4736; (active 2365, placebo 2371).
• Mean systolic at entry BP – 170, mean diastolic – 77
• Mean age – 72 (57% women)
• RX; chlorthalidone with a step-up to atenolol or reserpine if 
needed
Step I – chlorthalidone 12.5 mg/day or Placebo
Step II – CTD 25 mg/day or Placebo
Step III – CTD 25 + Atenolol 25 mg/day or Placebo
Step IV – CTD 25 + Atenolol 50 mg/day
Step IV – CTD25 + Reserpine 0.05 mg/day
K supplement PRN for K < 3.5 meq/l
• Average follow-up – 4.5 years
• Average BP at study end (control vs. active RX) – 155/72 vs. 
143/65
• Incidence of stroke – 8.2 vs. 5.2% (RRR 36%)
• Incident of MI – 141 vs. 106 (RRR 23%)
• Incidence of CVD – 414 vs. 289 (RRR 22%)
• Deaths from all cause – 242 vs. 213 (RRR 13%)
Treatment of Mild Hypertension study (TOMHS) 1993
Randomized controlled trial that compared efficacy of 5 classes 
of antihypertensive drugs along with non-pharmacologic 
treatments
The TOMHS trial (23) was a randomized double-blind placebo 
controlled trial set up to compare the BP lowering effects of six 
treatment regimen in patients with stage 1 hypertension (defined 
as diastolic blood pressure DBP 90–99 mmHg and systolic blood 
pressure, SBP 140–159 mmHg).
The six treatment regimens were:
 1. Placebo(nutritional-hygienic advice) n = 234
 2. Chlorthalidone + nutritional-hygienic advice, n = 136
 3. Acebutolol + nutritional-hygienic advice, n = 132
 4. Doxazosin mesylate + nutritional-hygienic advice, n = 134
 5. Amlodipine + nutritional-hygienic advice, n = 131
 6. Enalapril + nutritional-hygienic advice, n = 135
Nutritional hygienic advice included increase in physical 
activity, weight reduction, lowering salt intake, and reducing 
number of alcoholic drinks.
Outcomes: all six groups had sizeable BP reductions with mini-
mal differences between individual Drug intervention groups.
• Blood pressure: drug treatment vs. placebo (−15.9 vs. 
−9.1 mmHg for SBP and −12.3 vs. −8.6 mmHg for DBP).
• Death or non-fatal cardiovascular event: drug treatment vs. 
placebo (5.1 vs. 7.3%, p = 0.21).
• Other clinical events: drug treatment vs. placebo (11.1 vs. 
16.2%, p = 0.03).
Based on the results, the investigators concluded that inter-
vention with a drug and nutritional–hygienic advice was better 
compared to only nutritional–hygienic advice for treatment of 
mild hypertension.
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Dietary Approaches to Stop Hypertension (DASH) 1997
Randomized controlled trial to determine if Mediterranean 
type diet with or without salt restriction lowers BP. This is 
one of the best prospective interventional diet studies in the 
hypertension research.
Up until the 1990s, the non-pharmacological efforts to reduce 
blood pressure relied on a mix of weight control, reduced salt 
intake, reduced alcohol intake, and to an extent increase in dietary 
potassium. Earlier studies examining the relationship between 
diet and blood pressure found small and inconsistent changes in 
BP by nutrients such as potassium, calcium, magnesium, protein, 
and fiber. But most of these studies were retrospective in nature 
based on diet recall. In 1994, the first phase of the prospective 
DASH study was initiated (24).
Design: multicenter, prospective, randomized controlled trial
Participants: 459, SBP  <  160  mmHg, DBP between 80 and 
95 mmHg, 133 hypertensive
Intervention: three sets of diets using prepared meal
• Control diet, comparable to the average American diet – potas-
sium, calcium and magnesium at the 25th percentile of US 
consumption. Sodium 3 g.
• Rich in fruits and vegetables diet – potassium, calcium, mag-
nesium at 75th percentile of US consumption with high fiber. 
Sodium 3 g.
• Combination diet  –  plenty of fruits and vegetables (9–10 
servings/day), whole grain cereals, low fat dairy products and 
reduced saturated and total fat (Known now as DASH diet).
• All participants were initially fed control diet for 3 weeks (run 
in phase) followed by randomization for 8 weeks (intervention 
phase) into one of the diet groups.
Results
• In the hypertensive subset, combination diet reduced SBP 
and DBP by 11.4 and 5.5  mmHg, respectively, over the 
reduction by the control diet (p < 0.001).
• In the non-hypertensive subset, combination diet reduced 
SBP and DBP by 5.5 and 3.0 mmHg, respectively, over the 
control diet.
Low Sodium DASH:
This part of the DASH trial evaluated the effect of lowering salt 
intake in combination with the DASH diet. Completed 4 years 
after the original DASH trial (2001), this part of the study had 
412 participants randomized to DASH or control diet and within 
each of these 2 categories there were 3 levels of sodium intake: 
3.5, 2.3, and 1.2 g daily.
Results:
High salt +  control diet vs. Int salt +  control-Sys BP lowered 
2.1 mmHg
High salt +  DASH diet vs. Int salt +  DASH-Sys BP lowered 
1.3 mmHg
Int slat +  control diet vs. low salt +  control-Sys BP lowered 
4.6 mmHg
Int Salt  +  DASH diet vs. low salt  +  DASH Sys BP lowered 
1.7 mmHg
There was additive BP lowering effect on already lowered 
BP with DASH diet with every lowered level of salt intake. Not 
surprisingly, benefit of BP lowering effect of low salt was more 
pronounced in the control diet. The best BP lowering was in the 
low salt DASH diet. Compared to the control with high salt diet 
DASH/low salt reduced BP by 7.1 and 11.5 mmHg in normoten-
sive and hypertensive participants, respectively.
Medical research Council: Double-blind randomised trial 
of modest salt restriction in older people 1997
First study to explore effect of salt reduction in older people 
with normal range BP
At the time of the study, it was well known that high blood 
pressure could lead to stroke in older people. What was also 
known was that older people with normotensive blood pressure 
could also develop stroke. However, no efforts were made to lower 
the blood pressure in normotensive older people. The MRC study 
(25) aimed to answer just that question. The key highlights of the 
study are as below.
• Design: this double-blind randomized controlled cross-
over trial explored the effect that salt reduction would 
have on blood pressure in such individuals. The study 
participants included both normotensive and hypertensive 
individuals.
• In all 47 people were parts of the trial of which 18 were normo-
tensive and 29 were hypertensive.
• In the normal salt intake for the UK population group, supine 
blood pressure was 163/90 (SD 21/10) mmHg with urinary 
sodium excretion of 177 (49) mmol/day.
• With modest sodium restriction, blood pressure fell to 156/87 
(22/9) mmHg (p < 0.001) with a urinary sodium excretion of 
94 (50) mmol/day.
• A reduction in sodium intake of 83  mmol/day was asso-
ciated with a reduction of 7.2/3.2  mmHg. There was no 
significant difference in the blood pressure fall between 18 
normotensive and 29 hypertensive participants (8.2/3.9 vs. 
6.6/2.7 mmHg).
Hypertension Optimal Treatment (HOT) 1998
First large randomized control trial to determine if lowering 
target diastolic blood pressure below 90 mmHg reduces CV 
events further.
Since the second VA co-operative study, diastolic BP 
target had been 90  mmHg. No large trial was done since then 
to see if further lowering was beneficial. The Hypertension 
Optimal Treatment (26) (HOT) was a large multicenter trial 
designed to examine if lowering target diastolic pressure to 
85 or 80  mmHg reduces CV events or mortality. A secondary 
objective of this study was to examine the effect of low dose 
aspirin in preventing stroke further persons with treated 
hypertension.
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• Randomized control trial across 26 countries
• 18,790 patients in the age group of 50–80
• Diastolic blood pressure (DBP) between 100 and 1115 mmHg
• Three target Diastolic BP goal:
 ∘ DBP ≤ 90 mmHg (n = 6264)
 ∘ DBP ≤ 85 mmHg (n = 6264)
 ∘ DBP ≤ 80 mmHg (n = 6262)
• Meds used (same in all group): felodipine 5 mg daily to start 
and go up to 10 mg, add Ace inhibitor or beta blocker if target 
not achieved and finally add thiazide diuretic if still above 
target
• Additionally
 ∘ 9399 received acetylsalicylic acid
 ∘ 9391 received placebo
• Findings
 ∘ 20.3 mmHg reduction in DBP ≤ 90 mmHg group
 ∘ 22.3 mmHg reduction in DBP ≤ 85 mmHg group
 ∘ 24.3 mmHg reduction in DBP ≤ 80 mmHg group
The final result of the study failed to show any significant dif-
ference in outcome between all three groups. However, the actual 
achieved mean diastolic BP for the ≤90, ≤85, or ≤80  mmHg 
groups was 85, 83, and 81 mmHg, respectively. The difference in 
actual achieved diastolic BP degree of blood pressure reduction 
among the three groups was much smaller than the planned dif-
ference of 5 mmHg. So, the study failed to provide the power to 
detect any difference in protection with varying degrees of blood 
pressure lowering.
United Kingdom Prospective Diabetes Study (UKPDS) 
1998
Largest and longest trial examining efficacy and outcome of 
different treatment modalities for T2DM one arm of which 
examined the treatment for hypertension in T2DM.
The United Kingdom Prospective Diabetes Study (27, 28) was 
set up to find answers for several key questions related to diabetes 
management. Two key questions that the study aimed to answer 
in relation to hypertension were (1) did tight control of blood 
pressure in diabetics have an effect on complications and (2) 
was there any specific advantage or disadvantage of using a beta 
blocker or angiotensin converting enzyme inhibitor in treating 
hypertension in this population.
Design: randomized control trial
Two groups:
• Tight blood pressure control (target  <  150/85  mmHg), 
n = 758
• Less tight control group (target < 180/105 mmHg), n = 390
Results: tight control vs. light control
• Achieved Mean BP: 144/82 vs. 154/87 mmHg (p < 0.0001).
Reductions in risk of (Tight BP control vs. light BP control)
• Diabetes-related end points (microvascular complica-
tions) = 24% (95% CI 8–38%, p = 0.0046)
• Deaths related to diabetics  =  32% (95% CI 6–51%, 
p = 0.019)
• Strokes = 44% (95%CI 11–65%, p = 0.013)
• Microvascular end points  =  37% (95% CI 11–56%, 
p = 0.0092)
• Deterioration of retinopathy  =  34% (99% CI 11–50%, 
p = 0.004)
• Deterioration in visual acuity  =  47% (99% CI 7–70%, 
p = 0.004)
The study concluded that tight blood pressure control offered 
very significant benefits in various categories much more so than 
tight blood sugar control.
Of the 758 patients in tight BP control group 400 was allocated 
to treatment with captopril and 358 to atenolol. Mean achieved 
BP were 144/83 and 143/81 in captopril and atenolol groups, 
respectively. Captopril and atenolol were equally effective in 
reducing macro and microvascular endpoints.
African American Study of Kidney Disease (AASK) 2002
Landmark study in African Americans for determining target 
blood pressure and suitable drug regimen in hypertension 
control to prevent progressive renal failure. The study failed 
to show benefits of tight BP control over usual control to slow 
decline in GFR.
Hypertension is the second leading cause of End Stage Renal 
Disease (ESRD) and African-Americans are six times likelier to 
progress to ESRD from hypertension as compared to whites (29). 
The African-American Study of Kidney Disease published in 2002 
(21), compared the effects of two levels of blood pressure control 
and three drug regimens on the rate of decline in glomerular 
filtration rate(GFR) in African-Americans with hypertension and 
chronic kidney disease (CKD).
Design: 2 × 2 factorial design Randomized control trial.
Inclusion criteria:
• African-Americans
• 18–70 years of age
• Hypertensive renal disease (GFR, 20–65  ml/min per 
1.73 m2)
Intervention groups
Goal BP:
Gr. A. Lower mean arterial pressure group (target BP 
92 mmHg or less), n = 540
Gr. B Usual mean arterial pressure groups (BP 102–
107 mmHg), n = 554
Each group then was randomized to three different classes of 
antihypertensive agents
• Beta blocker (metoprolol), n = 441
• Angiotensin converting enzyme inhibitor (Ramipril), 
n = 436
• Dihydropyridine calcium channel blocker (Amlodipine), 
n = 217
All patients could use diuretics, direct vasodilator, alpha 
blocker, and central sympatholyitics as needed (in addition to 
lifestyle changes to lower salt intakes, etc.) to reach goal BP.
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Outcomes:
Lower target BP group vs. usual BP group
• Achieved BP
∘  128/78 mmHg, SD (12/8 mmHg) vs. 141/85 mmHg, SD 
(12/7 mmHg)
• Mean (SE) GFR slope
∘  1-2.21 (0.17) ml/min per 1.73 m2/year vs. −1.95 (0.17) 
ml/min per 1.73m2 per year (p = 0.24)
• Composite clinical outcomes risk reduction for lower blood 
pressure group
∘  2% (95% CI −22 to 21%; p = 0.85)
Drug comparison
• Risk reduction in composite clinical outcome
∘  Ramipril vs. metoprolol, 22% (95% CI 1–38%, p = 0.04)
∘  Ramipril vs. amlodipine, 38% (95% CI 14–56%, 
p = 0.004)
The authors observed that there was no significant slowing of 
disease progression (hypertensive nephrosclerosis) with a lower 
target BP. However, the results suggested that Ramipril was more 
effective compared to amlodipine in slowing decline in GFR. 
Superiority of Ramipril over Metoprolol was just marginal.
Antihypertensive and Lipid Lowering Treatment to Prevent 
Heart Attack Trial (ALLHAT) 2002
Largest antihypertensive trial. Resolved the question of supe-
riority of any of the newer class of antihypertensive drugs over 
the old thiazide like diuretic Chlorthalidone.
This large trial involving about 42,000 participants were 
designed to answer the important and lingering question 
whether newer classes of drugs such as angiotensin converting 
enzyme inhibitor (ACEI), calcium channel blocker (CCB), and 
alpha blocker give better CV outcomes than the older drugs such 
as thiazide diuretics (30).
Design: double-blind randomized control trial
Participants: patients, aged over 55 years with treated or untreated 
hypertension, with one additional Coronary heart disease risk factor.
The participants were from USA and Canada with 35% partici-
pants from AA community.
Four groups:
Chlorthalidone chosen drug representing thiazide/thiazide-like 
diuretics.
Total participants (15,525, higher than other groups since each of 
the other was being compared to this group);
Amlodipine represented CCB (n = 9048);
Lisinopril represented ACEI (n = 9054);
Doxazosin represented alpha blocker (n ~ 9061).
Outcome measures: the Doxazosin arm was terminated early 
when interim analysis by safety monitoring board concluded 
that there was a very high incidence of congestive heart failure 
in this arm. Outcome analyses on all the primary and secondary 
outcomes were done on the remaining three arms.
Results:
• Primary – fatal CHD or non-fatal MI
• Secondary  –  all cause mortality, stroke, combined CHD, 
combined CVD
Main results:
Primary outcomes: n = 2956; Chlorthalidone (11.5%); Amlodipine 
(11.3%), Lisinopril (11.4%);
Compared with Chlorthalidone, RR of Amlodipine was 0.98 
(95% CI 0.90–1.07);
Compared with Chlorthalidone RR of Lisinopril was 0.99 (95% 
CI 0.91–1.08).
Key Secondary outcomes
• Amlodipine vs. Chlorthalidone for heart failure (10.2 vs. 7.7%; 
RR 1.38; 95% CI 1.25–1.52)
• Lisinopril vs. Chlorthalidone
∘  For CVD (33.3 vs. 30.9%; RR 1.10; 95% CI 1.05–1.16)
∘  For stroke (6.3 vs. 5.6%; RR 1.15; 95% CI 1.02–1.30)
∘  For Heart Failure (8.7 vs. 7.7%; RR, 1.19; 95% CI 1.07–1.31)
Based on these findings, ALLHAT study authors concluded 
that thiazide should be the preferred antihypertensive to start 
with unless there is clear contraindication. However, it was an 
optimistic generalization about thiazide as a group and future 
studies and analysis showed that all thiazides are not similarly 
effective and the benefits of Chlorthalidone as antihypertensive 
is not equaled by commonly used hydrochlorothiazide.
Australian National Blood Pressure Study (ANBP II) 2003
Contemporary to ALLHAT study, done in a different popula-
tion but with same goal of comparison of thiazide vs. Ace 
inhibitor as antihypertensive drug
The results of the Second Australian National Blood Pressure 
Study (ANBP2) followed soon after ALLHAT results were pub-
lished. This was a randomized, open-label, blinded end point study 
of 6083 hypertensive patients aged 65–84 years, who otherwise 
had a relatively low cardiovascular risk profile, with a median 
follow-up of 4.1  years (31). Initial treatment options included 
ACE-I or a diuretics-based regimen (HCTZ and Enalapril were 
the recommended agents). The key findings from the study were:
Intervention: enalapril vs. HCTZ
 • All CV events or death from any cause
 – HR = 0.89 (0.79–1.00), p = 0.05
 – CVD: HR = 0.88 (0.77–1.01), p = 0.07
 – CHD: HR = 0.86 (0.70–1.06), p = 0.16
 – Stroke: HR = 1.02 (0.78–1.33), p = 0.91
 – HF: HR = 0.85 (0.62–1.18), p = 0.33
Anglo-Scandinavian Cardiac Outcomes Trial-Blood 
Pressure Lowering Arm ASCOT BPLA 2005
After the comparison of individual antihypertensive trials, 
next series of trials focused on the outcome with different 
combinations of antihypertensive drugs. ASCOT was one 
such early trial comparing CCB and ACEI with Beta blocker 
and thiazide diuretic
Published in 2005 the Anglo-Scandinavian Cardiac Outcomes 
Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) (32) was a 
randomized, open-label, blinded end point, controlled study. The 
main aim of the study was to compare two treatment regimens; 
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atenolol and a thiazide (representing the older drugs) vs. amlodi-
pine and perindopril (the newer classes).
Design: international multi-center randomized control trial
Participants: total 19,257 hypertensives male and female in the 
age group of 40–79 years, having at least one additional cardio-
vascular risk factors.
Two regimens
 • Amlodipine ± perindopril (n = 9639) vs. Atenolol ± bendro-
flumethiazide (n = 9618)
Primary end point: non-fatal MI and fatal CHD
Outcomes: amlodipine regimen vs. atenolol regimen
Primary end point – (429 vs. 474; unadjusted HR 0.90, 95% CI 
0.79–1.02, p = 0.1052)
Fatal and non-fatal stroke  –  (327 vs. 422; HR, 0.77, 95% CI 
0.66–0.89, p = 0.0003)
Total cardio-vascular events and procedures  –  (1362 vs.1602, 
HR,0.84, 95% CI 0.78–0.90, p < 0.0001)
All-cause mortality – (738 vs. 820, HR 0.89, 95% CI 0.81–0.99, 
p = 0.025)
Incidence of diabetes – (567 vs. 799, HR 0.70, 95% CI 0.63–0.78, 
p < 0.0001)
The results suggested that use of a CCB with addition of ACEI 
gives much better outcome than older regimen of beta blocker 
and thiazide.
Of note, this study like ANBP was open label trial (unlike 
ALLHAT) and used hydrochlorothiazide representing the thi-
azide class (not Chlorthalidone as in ALLHAT and other NIH 
sponsored studies). These crucial differences possibly account for 
different result in ANBP compared to ALLHAT.
Conduit Artery Function Evaluation (CAFE) 2006
This is a substudy of the ASCOT and this is the only large 
study that examined the variable effect of different class of 
drugs on reducing central aortic pressure (as measured by 
the new non-invasive technique of applanation tonometry) 
vs. usual peripheral blood pressures(brachial pressure). This 
study gave answer to the lingering question why beta blocker 
like atenolol was not very effective in reducing stroke in 
hypertensive patients.
The CAFE study (33) was a large sub study of the ASCOT trial. 
The CAFE trial was primarily designed to investigate differences 
in central aortic pressures vs. cuff BP in the two groups in ASCOT 
participants. The secondary aim of the trial was to examine if a 
relationship existed between central aortic pressures and cardio-
vascular outcomes. The central aortic BP was measured by use of 
applanation tonometry (Sphygmocore).
Total participants 2199.
Atenolol based (n = 1031)
Amlodipine based (n = 1042)
Baseline seated BP for two groups:
Atenolol based: 159.9/92.4 mmHg
Amlodipine based: 161/92.6 mmHg
Outcomes:
• Brachial BP lowering:
 ∘ Atenolol: down to 133.9/78.6 (lowered −26/−13.8 mmHg)
 ∘ Amlodipine Down to 133.2/76.9 (−27.8/−15.7 mmHg)
• Difference between two groups: 0.7/1.6 (p = 0.2)
• Central BP
 ∘ Atenolol: 125.5/79 mmHg
 ∘ Amlodipine: 121.2/77.8 mmHg
 ∘ Difference between two groups: 4.3/1.4 (p < 0.0001)
The authors concluded that different BP lowering drugs can 
have different effects on the central aortic pressure and that 
could possibly explain the difference in outcomes of different 
anti-hypertensive drugs.
Hypertension in the Very Elderly Trial (HYVET) 2008
First randomized trial to demonstrate benefits of treating 
hypertension in very elderly
Prior to the HYVET (34) trial, there were conflicting views 
on treating very old patients with hypertension. There were 
some studies which suggested that blood pressure and death 
were inversely related, possibly because of adverse effects of 
treatment. Some studies suggested decreased strokes and heart 
failure amongst treated older populations while many studies 
enrolled very few older population, so as not to be able to derive 
any significant conclusion. The HYVET trial aimed to address 
these issues and enrolled 3845 patients across Australasia, China, 
Europe, and Tunisia. The results from the trial summarized below 
suggest that treatment of hypertension in the very elderly clearly 
is beneficial on all accounts.
Design: randomized control trial
Inclusion criteria:
• 80 years or older
• Systolic blood pressure > 160 mmHg
Regimens:
• Active treatment (indapamide with or without perindopril) 
n = 1933
• Placebo group, n = 1912
Outcomes:
• BP in the active treatment group was 15/6.1  mmHg lower 
than the placebo group
In the intent to treat analysis, the active treatment group had
• 30% reduction in the rate of fatal and non-fatal stroke (95% 
CI −1 to 51, p = 0.06)
• 39% reduction in rate of death from stroke (95% CI 1–62, 
p = 0.05)
• 21% reduction in rate of death from any causes (95% CI 
4–35, p = 0.02)
• 23% reduction in the rate of death from cardiovascular 
causes (95% CI −1 to 40, p = 0.06)
• 64% reduction in the rate of heart failure (95% CI 42–78, 
p < 0.001)
• Side effects: active treatment vs. placebo (358 vs. 448, 
p = 0.001)
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Avoiding Cardiovascular Events through Combination 
Therapy in Patients Living with Systolic Hypertension 
(ACCOMPLISH) 2008
Large randomized trial that compared two commonly used 
treatment regimens (ACE + CCB vs. ACE + diuretic)
The Avoiding Cardiovascular Events through Combination 
Therapy in Patients Living with Systolic Hypertension 
(ACCOMPLISH) trial (35) explored the hypothesis that treatment 
of hypertensive patients, at a risk of cardiovascular disease was 
better with a combination of an angiotensin converting enzyme 
inhibitor (benazepril) and a calcium channel blocker (amlodi-
pine) than a combination of an ACE inhibitor (benazepril) and a 
diuretic (hydrochlorothiazide) as recommended by then prevail-
ing JNC 7 guidelines. The key findings of the study are as follows:
Design: double-blind, randomized
Participants: n = 11,506 patients with hypertension with at least 
one additional CV risk factors
Regimens: Benazepril + Amlodipine (n = 5744) vs. Benazepril + 
Hydrochlorothiazide (n = 5762)
Mean blood pressure after dose adjustment
• Benazepril + Amlodipine = 131.6/73.3 mmHg
• Benazepril + Hydrochlorothiazide = 132.5/74.4 mmHg
Outcome events: (a composite of death from cardiovascular 
causes, non-fatal myocardial infarction, non-fatal stroke, hospi-
talization for angina, resuscitation after sudden cardiac death, or 
coronary revascularization)
• Benazepril + Amlodipine = 552 (9.6%)
• Benazepril + Hydrochlorothiazide = 679 (11.8%)
2.2% absolute risk reduction with Benazepril + Amlodipine
19.6% relative risk reduction with Benazepril + Amlodipine 
(hazard ratio, 0.80, 95% CI 0.72–0.90, p < 0.001).
At the end of the study, which was stopped prematurely after 
attaining a pre-determined end point, the authors concluded 
that the ACEI and CCB combination was superior to the ACEI 
and diuretic combination in reducing cardiovascular events in 
patients with hypertension at risk for CV events.
The two major studies, ASCOT-BPLA and ACCOMPLISH, 
compared the newer and popular regimens (CCB and ACEI) vs. 
older drugs such as beta blockers and thiazide diuretics. Both 
were very large studies, but both were open label and sponsored 
by pharmaceutical companies. One of the major weaknesses in 
accepting the conclusion of thiazide being less effective than 
CCB when in combination with another class is that these studies 
invariably used a weak thiazide diuretic like hydrochlorothiazide. 
All NIH studies used Chlorthalidone and not hydrochlo rothiazide 
as the diuretic. A recent network meta-analysis had confirmed 
that Chlorthalidone is much superior to hydrochlorothiazide 
in efficacy and cardiovascular outcomes. Why these two studies 
used hydrochlorothiazide when a superior drug, Chlorthalidone 
was available is open to speculation.
Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) 2010
Until ACCORD studies, prevailing wisdom was in diabetic 
lower the BP is better but this notion was not evidence based. 
ACCORD trial was designed to answer this very important 
question.
The Joint National Committee on Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure (JNC 7) 
recommended lowering systolic blood pressure to <130 mmHg 
in diabetics (30). The Action to Control Cardiovascular Risk in 
Diabetes (ACCORD) trial (36) tested the effect of lowering the 
systolic blood pressure to <120 mmHg on cardiovascular events 
in diabetic patients compared to the usual systolic 140. The pri-
mary findings of the study were as follows:
Design: double-blind randomized control trial
No of participants # 4733
• Intensive therapy (IT, target systolic BP  <  120  mmHg) 
n = 2362
• Standard therapy (ST, target systolic BP  <  140  mmHg) 
n = 2371
Primary outcome = non-fatal MI, non-fatal stroke, or death from 
any cardiovascular causes
At the end of study with mean follow-up of 4.7 years:
Mean systolic BP: (IT) 119.3 mmHg vs. (ST) 133.5 mmHg
Primary outcome rate: 1.87% (IT) vs. 2.09% (ST) (hazard ratio, 
0.59; 95% CI 0.73–1.06, p = 0.20)
Annual rate of death (any cause): 1.28% (IT) vs. 1.19% (ST) 
(HR, 1.07; 95% CI 0.85–1.35, p = 0.55)
Annual rate of stroke: 0.32% (IT) vs. 0.53% (ST) (HR 0.59; 95% 
CI 0.39–0.89; p = 0.01)
Serious adverse events of anti HT therapy: IT – 77 (3.3%) vs. 
ST-30 (1.3%) (p < 0.001)
The authors concluded that compared to usual BP control 
intensive BP control in diabetics does not confer any significant 
benefit.
Primary Prevention of Cardiovascular Disease with a 
Mediterranean Diet (PREDIMED) 2013
First randomized control trial that studied the effect of a 
Mediterranean diet on Cardiovascular Disease
This was a large multicenter study (37) in Spain with over 7400 
participants enrolled in the study. There were three main groups. 
The first group was advised a diet with extra virgin olive oil, the 
second group with Mediterranean nuts, and the third with the 
control group.
Total participants = 7747
Age of participants = 55–80 years, 57% women
Median follow-up = 4.8 years
Primary cardio vascular end point occurred in 288 participants
Extra virgin olive oil = 96 events, adjusted Hazard ratio 0.70 
(95% CI 0.54–0.92)
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Mediterranean nuts =  83 events, adjusted Hazard ratio 0.72 
(95% CI 0.54–0.96)
Control group = 109 events
Systolic hypertension intervention trial (SPRINT) 2015
The SPRINT study conclusively demonstrated the benefit 
of lowering systolic blood pressure goal in a non-diabetic 
population.
The SPRINT (38) study was someway similar to ACCORD 
study but was in non-diabetics and without any prior history 
of stroke. It enrolled about 9000 participants, many of them 
elderly and with stage 2–4 chronic kidney disease. The study 
was stopped in the first week of September 2015 per recom-
mendation of the DSMB due to huge reduction in mortality 
(25%) and CV events (30%) in the group with systolic BP 
goal of 120.
Total participants = 9361
Intensive Blood Pressure control group (systolic  < 
120 mmHg) = 4678
Standard Blood Pressure control group (systolic  < 
140 mmHg) = 4683
Primary end point was myocardial infarction, acute coronary 
syndrome, stroke, heart failure, or death from cardiovascular 
events.
At the end of 1 year systolic blood pressure achieved was
121.4 mmHg in the intensive treatment group
136.2 mmHg in standard control group
Median follow-up = 3.26 years
Primary composite outcome  =  (1.65 vs. 2.19% per year) 
intensive vs. standard, respectively. Hazard ratio in the inten-
sive treatment group was 0.75; 95% confidence interval (CI), 
0.64–0.89; (p < 0.001).
All cause mortality was found to be lower in the intensive treat-
ment group: (hazard ratio, 0.73; 95% CI 0.60–0.90; p = 0.003).
CONCLUSiON
Hypertension is still the most prevalent of all non- communicable 
chronic disease (NCCD) throughout the world including less 
developed countries. Per NHNES survey of 2011–2012, the 
prevalence of hypertension in the US has remained around 
30% – and while awareness of hypertension has reached a lauda-
tory goal of 83% – the control rate is still only 50% (49% for men 
and 55% for women). These rates are also very similar among all 
ethnic groups. Therefore, though we have come a long way in the 
last 50 years in managing hypertension – from calling it essential 
to finding effective drug therapy for control – we are still short 
of truly overcoming this common malady of humanity. In fact, 
the annual number of deaths from HTN in the US still exceeds 
30,000. Moreover, our understanding of the pathophysiology of 
common or so-called “essential” hypertension is still incomplete 
in many ways. The new discovery of extra-renal deposition of 
excess sodium in the skin, modulated by macrophages, changed 
the paradigm of classical Guytonian frame work of salt and 
hypertension (39, 40). Similarly, the role of immunity, especially 
the central indispensable role of T-cell infiltration in the kidney 
for Angiotensin II-mediated hypertension also made the patho-
physiology of hypertension more complex (41, 42). Of course, 
there is the evolving understanding of the tremendous role played 
by the trillions of gut microbiota in health and disease overall, 
including hypertension (43). These are only a few of the many 
new developments in broadening our understanding of the 
pathophysiology of hypertension. Without understanding the 
disease (or possibly the complex of diseases that manifest as high 
BP), we cannot achieve true control over it.
We know many isolated small communities like Kuna Indians, 
who continue to follow their ancestral traditions, do not develop 
hypertension even in their very old age. It is possibly not gene-
related, since they develop hypertension when they immigrate to 
western communities (44, 45). Thus, we have to continue to strive 
to expand our knowledge of the physiology and epidemiology of 
hypertension and related diseases. We must explore other poten-
tial non-drug therapies. Renal sympathetic nerve ablation showed 
some initial promise but needs lots of work to determine its role 
(46). Similarly, the role of different lifestyle improvements includ-
ing optimal salt and fruits/vegetable intake, role of flavonoids from 
cocoa, coffee, or tea needs further exploration and refinement.
Regarding immediate clinic management of hypertension, a 
major unresolved issue is to define the exact clinical utility and 
wide applicability of ambulatory BP monitoring as well as the role 
of home BP monitoring. We know that the 24-h average BP per 
ABPM predicts hypertension outcome better than office BP – the 
standard used in almost all the trials cited above. We also know 
for the same level of office BP, people with non-dipping night BP 
has worse prognosis in CV outcomes (47). Wider use of ABPM 
can further reduce the high incidence of stroke and heart failure 
in the overall population.
There are many other worthy issues related to hypertension that 
we cannot adequately discuss in this space. We can only say that the 
great success in refining hypertension treatment, so far in the last 
50 years is truly only the beginning of a long journey. The challenge 
remains for the next generation of clinicians and researchers for 
further advancement as we better understand human biology.
The success of pharmacological treatment of a common 
human malady like hypertension that affects more than a billion 
of our fellow human beings is a mega achievement. In the history 
of modern medicine, only vaccination to prevent infectious dis-
eases, antibiotics for infections, and oral hydration for diarrheal 
diseases have had similar success and impact on global health.
In some ways, the success of treating this common chronic 
non-communicable disease (NCD)  –  as WHO has dubbed 
it – made way for effective planning to manage others. The success 
of multi-center RCTs for hypertension led to the concept of a very 
large multi-center study using one single variable intervention 
(aspirin for preventing CAD or ACE I for systolic heart failure) 
(48). In many ways, this eventually led to the modern concept of 
Evidence Based Medicine (EBM), which is now the cornerstone 
of scientific medicine.
In my experience in teaching medical students and residents, 
I noticed how little they know about these major breakthroughs 
in medicine especially cardiovascular medicine in the last quarter 
of the twentieth century and how the success of pharmacologic 
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treatment of hypertension started this revolution. Once they 
learned about it, they got a better perspective and better under-
standing of the evolving nature of the Evidence-Based Medicine. 
It is these trainees that I had in mind when I decided to create this 
timeline of the history of hypertension treatment. I hope that the 
next generation will carry on the spirit of learning and conquer 
the uncharted territory of this common malady that affects a 
billion men and women worldwide today.
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